UOL stock price climbs to S$10.31 as lower mortgage rates keep Singapore developers in focus
21 January 2026
1 min read

UOL stock price climbs to S$10.31 as lower mortgage rates keep Singapore developers in focus

Singapore, Jan 21, 2026, 15:01 SGT — Regular session

  • UOL shares rose roughly 0.7% to S$10.31 in afternoon trading, building on gains from the past two sessions
  • RHB maintained an overweight view on Singapore real estate stocks, citing lower mortgage benchmarks alongside strong pent-up demand
  • Traders are focused on URA’s upcoming quarterly property market update scheduled for Jan 23

Shares of UOL Group Limited edged up about 0.7% to S$10.31 by 2:59 p.m. local time Wednesday, pushing the stock’s rally into a second straight session. The Singapore property name saw volume hit around 2.4 million shares, with prices ranging from S$10.05 to S$10.40, according to the company’s investor page. 1

This shift is crucial as developers react sharply to changes in funding costs: when mortgages ease, demand usually picks up and balance sheets improve. That sets the stage for a January rally in the sector, despite valuations still trading below underlying asset values.

RHB Bank Singapore analyst Vijay Natarajan pointed to growing momentum in the sector, driven by “healthy wage growth, lower interest rates and pent-up demand,” in a Jan 20 research note cited by The Edge Singapore. He noted that sector discounts to revalued net asset value (RNAV) still hover above 40%, suggesting the sector could climb another 20%–30%. Natarajan also highlighted last year’s new home sales of 10,951 units excluding executive condominiums, and forecast the three-month Singapore Overnight Rate Average (SORA) to drop roughly 185 basis points to 1.2% by December 2025, which would push fixed mortgage rates down to about 1.55%–1.6%. 2

RNAV isn’t fixed; it shifts with appraisals and market sentiment. Traders use it as a quick gauge of “what the land and buildings might be worth.” A big discount can spark a rally if rates drop, but it can stick around if investors question asset sales, cash flow, or management’s ability to deliver.

SORA serves as the local benchmark rate, commonly used for home loans. A dip in SORA can lighten monthly payments for certain borrowers and reduce interest expenses for developers handling debt-heavy projects. However, the impact often filters through unevenly and takes time.

UOL finds itself caught in that tug-of-war. The stock typically mirrors sentiment on residential demand and financing conditions, often serving as a barometer for investor expectations on upcoming launches and pricing trends over the next few quarters.

That sensitivity works both ways. If mortgage rates halt their decline or home sales slump beyond forecasts, the rally could reverse fast—especially after such a narrow price surge. Policy changes that curb demand would add fuel to the sell-off.

Traders are set to eye the Urban Redevelopment Authority’s quarterly property market update on Jan 23 for new cues on demand and pricing. 3

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
DBS share price slips again as Trump tariff threats jar markets; Feb 9 results loom
Previous Story

DBS share price slips again as Trump tariff threats jar markets; Feb 9 results loom

Yangzijiang Shipbuilding stock stalls at S$3.48 as global jitters keep SGX shipbuilder in check
Next Story

Yangzijiang Shipbuilding stock stalls at S$3.48 as global jitters keep SGX shipbuilder in check

Go toTop